Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon May 21, 2021 11:03am

168 Views

Post# 33247688

Arch Biopartners Current Insider Ownership (58.06%)

Currently Insiders control:

35,687,265 Shares

The Company has 61,462,302 common shares outstanding.

Insiders Currently Control 58.06% of the companies outstanding shares leaving 25,775,040 held by non insiders including large holders.

This tightly held float could lead to an interesting supply demand situation with Phase II data expected in July 2021

(Information gathered from INKRESEARCH)

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario